137 related articles for article (PubMed ID: 35970353)
1. Factors Associated With Radioactive Iodine Therapy-Acquired Nasolacrimal Duct Obstruction.
Lee IT; Chen W; Chen Q; Cole HA; Bischoff LA; Jessop AC; Sobel RK
Endocr Pract; 2022 Dec; 28(12):1210-1215. PubMed ID: 35970353
[TBL] [Abstract][Full Text] [Related]
2. A Pilot Nonrandomized Controlled Trial Examining the Use of Artificial Tears on the Radioactivity of Tears After Radioactive Iodine Treatment for Thyroid Cancer.
Lee IT; Grice JV; Ji X; Chen Q; Bischoff LA; Jessop AC; Barahimi B; Codere F; Mawn LA; Sobel RK
Thyroid; 2024 Jan; 34(1):82-87. PubMed ID: 37917111
[No Abstract] [Full Text] [Related]
3. Surgical Risk Prediction for Nasolacrimal Duct Obstruction in Radioactive Iodine-Treated Thyroid Cancer: A Nationwide Cohort Study.
Lee JY; Woo KI
Thyroid; 2022 May; 32(5):544-551. PubMed ID: 34894720
[No Abstract] [Full Text] [Related]
4. Endoscopic dacryocystorhinostomy following radioactive iodine thyroid ablation.
Van Tassel SH; Segal KL; Hsu NM; Kacker A; Lelli GJ
Orbit; 2017 Apr; 36(2):59-63. PubMed ID: 28388347
[TBL] [Abstract][Full Text] [Related]
5. Salivary gland dysfunction and nasolacrimal duct obstruction: stenotic changes following I-131 therapy.
Savage MW; Sobel RK; Hoffman HT; Carter KD; Finkelstein MW; Shriver EM
Ophthalmic Plast Reconstr Surg; 2015; 31(3):e50-2. PubMed ID: 24836449
[TBL] [Abstract][Full Text] [Related]
6. [Lacrimal drainage system obstruction associated to radioactive iodine therapy for thyroid carcinoma].
Fonseca FL; Lunardelli P; Matayoshi S
Arq Bras Oftalmol; 2012; 75(2):97-100. PubMed ID: 22760799
[TBL] [Abstract][Full Text] [Related]
7. Outcomes of Endoscopic Dacryocystorhinostomy in Secondary Acquired Nasolacrimal Duct Obstruction: A Case-Control Study.
Sweeney AR; Davis GE; Chang SH; Amadi AJ
Ophthalmic Plast Reconstr Surg; 2018; 34(1):20-25. PubMed ID: 27997463
[TBL] [Abstract][Full Text] [Related]
8. Nasolacrimal duct obstruction associated with radioactive iodine therapy for thyroid carcinoma.
Shepler TR; Sherman SI; Faustina MM; Busaidy NL; Ahmadi MA; Esmaeli B
Ophthalmic Plast Reconstr Surg; 2003 Nov; 19(6):479-81. PubMed ID: 14625496
[TBL] [Abstract][Full Text] [Related]
9. Nasolacrimal duct obstruction following radioactive iodine 131 therapy in differentiated thyroid cancers: review of 19 cases.
Al-Qahtani KH; Al Asiri M; Tunio MA; Aljohani NJ; Bayoumi Y; Munir I; AlAyoubi A
Clin Ophthalmol; 2014; 8():2479-84. PubMed ID: 25525325
[TBL] [Abstract][Full Text] [Related]
10. Dependence of radioactive iodine-131 capture by the lacrimal ducts on the tear production level.
Yartsev VD; Sheremeta MS; Trukhin AA; Atkova EL; Degtyarev MV; Yasyuchenya VS; Yudakov DV
Indian J Ophthalmol; 2023 May; 71(5):1828-1832. PubMed ID: 37203037
[TBL] [Abstract][Full Text] [Related]
11. Nasolacrimal duct obstruction as a complication of iodine-131 therapy in patients with thyroid cancer.
Fard-Esfahani A; Farzanefar S; Fallahi B; Beiki D; Saghari M; Emami-Ardekani A; Majdi M; Eftekhari M
Nucl Med Commun; 2012 Oct; 33(10):1077-80. PubMed ID: 22825036
[TBL] [Abstract][Full Text] [Related]
12. The Microbiome of the Nasolacrimal System and Its Role in Nasolacrimal Duct Obstruction.
Curragh DS; Bassiouni A; Macias-Valle L; Vreugde S; Wormald PJ; Selva D; Psaltis AJ
Ophthalmic Plast Reconstr Surg; 2020; 36(1):80-85. PubMed ID: 31809480
[TBL] [Abstract][Full Text] [Related]
13. Relationship between radioactive iodine therapy for thyroid carcinoma and nasolacrimal drainage system obstruction.
Cetinkaya A; Kersten RC
Ophthalmic Plast Reconstr Surg; 2007; 23(6):496. PubMed ID: 18030131
[No Abstract] [Full Text] [Related]
14. Nasolacrimal drainage system obstruction from radioactive iodine therapy for thyroid carcinoma.
Kloos RT; Duvuuri V; Jhiang SM; Cahill KV; Foster JA; Burns JA
J Clin Endocrinol Metab; 2002 Dec; 87(12):5817-20. PubMed ID: 12466391
[TBL] [Abstract][Full Text] [Related]
15. Topographic and anatomical features of the nasolacrimal duct obstruction due to radioiodine treatment.
Yartsev VD; Atkova EL; Ekaterinchev MA
Int Ophthalmol; 2023 Sep; 43(9):3385-3390. PubMed ID: 37199817
[TBL] [Abstract][Full Text] [Related]
16. Resolution of congenital nasolacrimal duct obstruction with nonsurgical management.
Pediatric Eye Disease Investigator Group
Arch Ophthalmol; 2012 Jun; 130(6):730-4. PubMed ID: 22801833
[TBL] [Abstract][Full Text] [Related]
17. Nasolacrimal obstruction secondary to I(131) therapy.
Burns JA; Morgenstern KE; Cahill KV; Foster JA; Jhiang SM; Kloos RT
Ophthalmic Plast Reconstr Surg; 2004 Mar; 20(2):126-9. PubMed ID: 15083081
[TBL] [Abstract][Full Text] [Related]
18. Accumulation of 131Iodine in the nasolacrimal sac/duct after radioiodine therapy for papillary thyroid cancer.
Usmani S; Jain A; Al-Riyami K; Abubakar S
J Pak Med Assoc; 2023 Mar; 73(3):713-714. PubMed ID: 36932793
[TBL] [Abstract][Full Text] [Related]
19. Clinical characteristics of nasolacrimal duct obstruction after iodine therapy in differentiated thyroid cancer patients.
Li N; Zhang W
Ear Nose Throat J; 2023 Apr; ():1455613231170088. PubMed ID: 37070248
[TBL] [Abstract][Full Text] [Related]
20. Office probing for treatment of nasolacrimal duct obstruction in infants.
Miller AM; Chandler DL; Repka MX; Hoover DL; Lee KA; Melia M; Rychwalski PJ; Silbert DI; ; Beck RW; Crouch ER; Donahue S; Holmes JM; Quinn GE; Sala NA; Schloff S; Wallace DK; Foster NC; Frick KD; Golden RP; Lambert SR; Tien DR; Weakley DR
J AAPOS; 2014 Feb; 18(1):26-30. PubMed ID: 24568978
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
